The stock market is up Friday, with the Dow Jones Industrial Average up 0.33%, the Nasdaq up 0.59% and the S&P 500 up 0.43%. Today’s winners include a pharmaceutical company that received good news from the Food and Drug Administration and a home builder that beat Wall Street earnings expectations. Today’s losers include a pharmaceutical company who may not get European approval for a drug and a well-known mobile company that experienced outages overseas.
These are Friday’s market winners and losers.
Biggest Winners
Shares of Halozyme Therapeutics Inc. (NASDAQ: HALO) are up 26.52% to $8.11 on trading volume of 2 million shares. The U.S. Food and Drug Administration has provided guidance to Halozyme and ViroPharma Inc. (NASDAQ: VPHM) to resume clinical studies of the drug Cinryze. The 52-week high is $13.50.
Shares of KB Home (NYSE: KBH) are up 9.38% to $14.34 on trading volume of 7 million shares. The company earned 4 cents a share in the third quarter, better than a loss of 12 cents a share that Wall Street analysts polled by Reuters were expecting. Before Friday, the 52-week high was $13.65.
Biggest Losers
Shares of VIVUS Inc. (NASDAQ: VVUS) are down 10.58% to $21.21 on trading volume of 4.7 million shares. The pharmaceutical company is concerned that European regulators will reject its anti-obesity drug. The 52-week low is $7.47.
Shares of Research In Motion Ltd. (NASDAQ: RIMM) are down 5.58% to $6.52 on trading volume of 10.4 million shares. Blackberry suffered service outages in Europe, the Middle East and Africa. The 52-week low is $6.33.
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.